NATCO Pharma Commits $2 Million Investment in Cellogen Therapeutics, Discloses Consistent Communication of Company Performance and Price-Sensitive Information

In a recent financial document, NATCO Pharma clarified a news item regarding their potential acquisition plans and investments in Cellogen Therapeutics. The company confirmed that all information in the article was derived from publicly disclosed materials. NATCO Pharma has committed to investing US$ 2 million in Cellogen Therapeutics, a research company focused on cell and gene therapies, with a particular focus on CAR-T therapy. This investment will be made in three tranches, with the first tranche of INR 7.51 crores already invested. The company has also consistently communicated price-sensitive information and events to the stock exchanges, adhering to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. They have not withheld any material information that could impact the movement in the price of their securities.